0001157523-15-000276.txt : 20150130 0001157523-15-000276.hdr.sgml : 20150130 20150129201049 ACCESSION NUMBER: 0001157523-15-000276 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150129 FILED AS OF DATE: 20150130 DATE AS OF CHANGE: 20150129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 15560536 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 6-K 1 a51029697.htm AURINIA PHARMACEUTICALS INC. 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

Dated January 29, 2015

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant’s principle executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ⃞     Form 40-F  ⊠

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ⃞     No  ⊠

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:

January 29, 2015

 

Aurinia Pharmaceuticals Inc.

 

 

 

By:

/s/ Michael R. Martin

Name:

Michael R. Martin

 

 

Title:

Chief Operating Officer

2

EXHIBIT INDEX

Exhibit

 

Description of Exhibit

 
99.1

News Release – Aurinia Pharmaceuticals to Present at the BIO CEO Investor Conference

3

EX-99.1 2 a51029697ex99_1.htm EXHIBIT 99.1

Exhibit 99.1

Aurinia Pharmaceuticals to Present at the BIO CEO Investor Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--January 29, 2015--Aurinia Pharmaceuticals, Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its President and Chief Executive Officer Stephen Zaruby will present a corporate overview of the company at the BIO CEO Investor Conference, taking place February 9th-10th in New York at the Waldorf-Astoria Hotel. The presentation will also be available using the webcast link below.

Aurinia Presentation Details
Date: Tuesday, February 10th, 2015
Time: 3:00 p.m. Eastern Standard Time
Location: Waldorf-Astoria Hotel
Webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2015/69221498302.cfm

About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Visit www.auriniapharma.com for more information.

CONTACT:
Aurinia Pharmaceuticals, Inc.
Company Contact:
Stephen Zaruby, 250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investor & Media Contact:
Michael R. Martin, 250-708-4272
Chief Operating Officer
mmartin@auriniapharma.com